BOEHRINGER-INGELHEIM
7.7.2020 14:02:14 CEST | Business Wire | Press release
Boehringer Ingelheim and Numab Therapeutics (Numab) today announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects aiming at novel therapies for difficult-to-treat lung and gastrointestinal (GI) cancers and patients with geographic atrophy (GA), a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. The collaboration brings together Boehringer Ingelheim’s leading expertise in the research and development of life changing breakthrough therapies with Numab’s multi-specific antibody platform.
Lung and GI cancers and retinal diseases are key focus areas of Boehringer Ingelheim’s research and development program. In oncology the company has built a broad and diverse pipeline, combining cancer immunology and cancer cell directed approaches. The novel T-cell engager to be developed with Numab adds to Boehringer Ingelheim’s growing cancer immunology portfolio and supports the strategy to take cancer on by targeting ‘cold’ tumors with synergistic combination approaches. In retinal diseases Boehringer Ingelheim is pursuing a holistic approach leveraging existing expertise in oncology, inflammation, neurodegeneration, fibrosis and cardiometabolic diseases. The new GA program with Numab further broadens the company’s comprehensive portfolio of next generation retinal therapy approaches in various stages of development up to Phase 2 in macular degeneration and diabetic retinal diseases.
“We are thrilled to work with the excellent team at Numab to advance our portfolio assets. Numab’s technology platform fits well with our internal antibody discovery and engineering capabilities and will enhance our efforts to deliver transformative antibody-based therapeutics to patients,” said Paige Mahaney, SVP and US Discovery Research Site Head at Boehringer Ingelheim.
“We are looking forward to working with Boehringer Ingelheim, a global leader in pharmaceutical R&D with profound expertise across a broad spectrum of therapeutic areas, further validating our technology platform. This addition to our growing roster of partnerships represents another key milestone in our business development efforts,” commented Dr. Oliver Middendorp, Chief Business Officer of Numab Therapeutics. “The upfront payment and near-term milestones attached to this alliance will further strengthen Numab’s ability to accelerate the development of key proprietary assets.”
Under the terms of the alliance, the partners will work together to discover one novel multi-specific antibody drug candidate in each area. Boehringer Ingelheim receives from Numab an exclusive worldwide license to develop and commercialize the resulting candidates in exchange for upfront and milestone payments, as well as tiered royalties on net sales of all products resulting from the alliance.
With today’s announcement, Numab has been able to secure seven ongoing relationships with leading pharmaceutical companies including 3SBio / Sunshine Guojian, Boehringer Ingelheim, Eisai Co., Ltd., CStone Pharmaceuticals, Ono Pharmaceutical Co., Ltd., Kaken Pharmaceutical Co., Ltd., and Tillotts Pharma AG.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/numab
View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005453/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hilton Announces Exclusive Agreement with YOTEL to Expand Global Footprint in Lifestyle Segment19.3.2026 12:00:00 CET | Press release
Independent, design-led YOTEL brand gains reach through Hilton’s global distribution platformHilton Honors members gain access to a sleek, contemporary new way to stayYOTEL will be the first independent brand as part of newly established Select by Hilton brand Hilton (NYSE: HLT) today announced an exclusive agreement with YOTEL that will provide guests yet another way to stay within the hospitality leader’s growing global portfolio. With highly efficient hotels in urban markets, YOTEL has pioneered ways to meet changing guest needs through stays that feature smart room design, and clever tech-enabled features. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318705963/en/ YOTEL Boston The franchise agreement with YOTEL expands Hilton’s network, filling a distinct customer need in the growing lifestyle segment in a manner consistent with its proven asset-light model. YOTEL will continue to independently manage and license it
Keenfolks Launches KEENFOLKS X_19.3.2026 12:00:00 CET | Press release
A Global AI-Native Marketing Infrastructure Network for Enterprise GrowthKeenfolks, the AI transformation partner behind marketing initiatives for brands including Coca-Cola, Diageo, Mars, Reckitt, Nestlé and Merck-MSD, today announced the launch of KEENFOLKS X_, a new global marketing network designed to operate on shared AI infrastructure The traditional holding company model that has shaped global marketing for decades is facing increasing pressure as capital markets, consolidation activity, and client demands point to a need for structural change. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260319751842/en/ Miguel Machado, CEO and Co-Founder, Keenfolks The marketing industry is searching for a new model. The question is no longer whether agencies need to change, but which ones were built for this shift from the start. Keenfolks, the Integrative AI® partner built natively for the Age of Intelligence, today announces th
Infobip's 20-Year Analysis of 3.8 Trillion Messages Reveals Rise of Omnichannel, RCS and AI-Driven Communication19.3.2026 11:45:00 CET | Press release
Analysis of 628 billion interactions in 2025 highlights the shift to conversational experiences, with nearly 98% of traffic now sent by customers using multiple channels AI-first cloud communication platform Infobip has released its Messaging Trends Report 2026, offering an analysis of the state of business communication. Drawing on data from 628 billion mobile interactions in 2025 and a historical review of 3.8 trillion messages over the past 20 years, the report charts the evolution from single-channel messaging to complex, AI-powered omnichannel experiences. The data reveals a shift in how brands engage with customers. While SMS remains a critical pillar for reliability, accounting for 62% of traffic, the growth of rich, conversational channels is accelerating. RCS traffic grew 3x globally last year, with 70x increase in North America. WhatsApp continues to dominate the conversational landscape, facilitating 91% of all conversational AI interactions on the platform, marking a 25% in
REPLY Unveils the New Editions of the Reply AI Music Contest and Reply AI Film Festival under the Theme “Imaginatio Nova”19.3.2026 09:00:00 CET | Press release
This year once again, the top finalists of the music contest will perform live on stage at Kappa FuturFestival in Turin, while the finalists of the film contest will be invited to an event organised by Reply and Mastercard, to be held in September in Venice. Reply [EXM, STAR: REY, ISIN: IT0005282865] confirms its commitment for 2026 to fostering dialogue between creativity, technology and artificial intelligence through the Reply AI Music Contest and the Reply AI Film Festival, the two international AI competitions open to creatives, filmmakers, musicians and innovation professionals from around the world. The theme of the 2026 edition, “Imaginatio Nova”, is an invitation to explore a new phase of imagination, where human creativity is renewed through technology. This approach views artificial intelligence not as a substitute for artistic talent, but as a catalyst for new visions, languages and expressive possibilities, capable of generating forms that did not previously exist. This pr
Valeo Foods Group Accelerates Growth in Eastern Europe With Acquisition of Prestige-96, a Leading Bulgarian Sweet Baked Goods Player19.3.2026 08:00:00 CET | Press release
Valeo Foods Group, one of Europe’s leading producers of sweets, treats and snacks, today announced that it has reached an agreement to acquire 100% of Prestige-96 AD (“Prestige”), a market-leading Bulgarian manufacturer of sweet baked goods. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260319225232/en/ Prestige-96 sandwich biscuits. Founded in 1996, Prestige is one of Bulgaria’s most established and trusted producers of biscuits, wafers and sweet snack products. Its portfolio features some of the country’s most recognisable local brands including - Naya (Ная), Hyper (Хайпър), Mirage (Мираж) and Roden Kray (Роден Край). Prestige employs approximately 450 people across its operations. The acquisition marks a significant milestone in Valeo Foods Group’s long-term growth strategy, focused on acquiring market-leading, iconic local brands as part of its continued European expansion. As Valeo Foods Group’s eighth acquisition sinc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom